Zobrazeno 1 - 10
of 40
pro vyhledávání: '"W M Clark"'
Autor:
Alexander W. M. Clark Kenney
Publikováno v:
Ibis. 16:107-112
Publikováno v:
Stroke. 31:940-945
Background and Purpose —We investigated the combined effect of tissue plasminogen activator and ischemia on middle cerebral artery (MCA) reactivity to determine whether abnormal MCA function after 2 hours of ischemia was worse in arteries perfused
Autor:
W M, CLARK, E A, EVANS
Publikováno v:
Federation proceedings. 5
Autor:
G P, WRIGHT, W M, CLARK
Publikováno v:
Clinical science. 6(1-2)
Autor:
W M, Clark
Publikováno v:
Current opinion in drug discoverydevelopment. 2(6)
The increasing structural and stereochemical complexity of new drug candidates continues to pose numerous synthetic challenges for pharmaceutical process development. Often the implementation of new methodologies, and/or the novel utilization of exis
Autor:
H. Q. Sinclair, W. M. Clark
Publikováno v:
MD Conference Express. 10:11-12
Publikováno v:
Organic letters. 1(11)
[formula: see text] The bakers' yeast reduction of 3-(1,3-benzodioxol-5-yl)-6-propoxy-1H-inden-1-one 4 has been shown to give (S)-3-(1,3-benzodioxol-5-yl)-2,3-dihydro-6-propoxy-1H-indan-1-one 6 in 65% yield with high enantioselectivity (99.0% ee), a
Publikováno v:
Stroke. 31(6)
The goals of the present study were to assess the efficacy and safety of nalmefene (Cervene) in patients with acute (or =6 hours) ischemic stroke and to investigate the safety of combined recombinant tissue plasminogen activator and nalmefene in a se
Autor:
A, Furlan, R, Higashida, L, Wechsler, M, Gent, H, Rowley, C, Kase, M, Pessin, A, Ahuja, F, Callahan, W M, Clark, F, Silver, F, Rivera
Publikováno v:
JAMA. 282(21)
Intravenous tissue-type plasminogen activator can be beneficial to some patients when given within 3 hours of stroke onset, but many patients present later after stroke onset and alternative treatments are needed.To determine the clinical efficacy an
Autor:
J M, Hourihane, W M, Clark
Publikováno v:
Neuroimaging clinics of North America. 9(3)
This article reviews both the commonly used functional outcome scales and the detailed neurologic deficit scales that are currently employed in stroke therapeutic efficacy trials. Both types of scales have their apparent advantages, with the neurolog